CDC Website CDC Website

To Join the NPIN community or

You are here

Officers and Trustees Discretionary Grants

Centers for AIDS Research (P30 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Centers for AIDS Research (CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research.

Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Developmental Centers for AIDS Research (D-CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. D-CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. Additionally, D-CFARs provide support to assist investigators in the development of a competitive standard CFAR. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research.

Ryan White HIV/AIDS Program Part C Capacity Development Program

This notice announces the opportunity to apply for funding under the Health Resources and Services Administration’s (HRSA) Ryan White HIV/AIDS Program (RWHAP) Part C Capacity Development Program. The purpose of this program is to strengthen organizational capacity to respond to the changing health care landscape and increase access to high quality HIV primary health care services for low income, uninsured, and underserved people with HIV.

Novel Therapeutics Directed to Intracellular HIV Targets (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support the development of novel therapeutics which are directed to intracellular HIV targets. During the HIV life cycle multiple viral associated proteins are expressed in the infected cell. All are critical to support assembly, release and maturation of the virus. Considering each protein has a defined role in the life cycle, therapeutically targeting one or more may be an effective strategy to obtain potent antiviral activity.

Novel Imaging Approaches for detection of Persistent HIV and Neuroimmune dysfunction associated with HIV In the Central Nervous System (CNS) (R21 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites research applications to elucidate mechanisms of neuroimmune dysfunction caused by HIV-1 and to detect persistent/latent/reactivated HIV using novel imaging/neuroimaging approaches in the central nervous system in anti-retroviral therapy (ART) suppressed individuals. ?These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data.

Novel Imaging Approaches for detection of Persistent HIV and Neuroimmune dysfunction associated with HIV In the Central Nervous System (CNS) (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites research applications to elucidate mechanisms of neuroimmune dysfunction caused by HIV-1 and to detect persistent/latent/reactivated HIV using novel imaging/neuroimaging approaches in the central nervous system from anti-retroviral therapy (ART) suppressed individuals. Applications testing a fully conceptualized and hypothesis-based solid premise founded with adequate preliminary data should consider applying to the companion R21 announcement, RFA MH-20-331 .

Rapid Antiretroviral Therapy (ART) Start in the Ryan White HIV/AIDS Program – Dissemination Assistance Provider

This notice announces the opportunity to apply for fiscal year (FY) 2020 funding under the new 3-year program entitled Rapid Antiretroviral Therapy (ART) Start in the Ryan White HIV/AIDS Program – Dissemination Assistance Provider. The purpose of this Health Resources and Services Administration (HRSA) program is to fund a single organization that will develop a compendium of promising rapid ART interventions.

Transgender People: Immunity, Prevention, and Treatment (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).

Food as Medicine: Food Insecurity and HIV-related Comorbidities, Coinfections, and Complications within the Mission of the NIDDK (R01 Clinical Trial Optional)

This funding opportunity announcement (FOA) seeks US domestic research projects that address how food insecurity effects HIV comorbidities, coinfections, and complications (CCCs) within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The approaches may address the pathways linking food insecurity and the development or exacerbation of CCCs; or they may evaluate the mechanisms whereby interventions that alleviate food insecurity improve CCCs.

Subscribe to RSS - Officers and Trustees Discretionary Grants